California State University - Interdisciplinary Cancer Meeting (CSU-ICM)

加州州立大学 - 跨学科癌症会议 (CSU-ICM)

基本信息

项目摘要

R13 Application Kelber, Tamae, De Bellard, Bermudes Title: The California State University – Interdisciplinary Cancer Meeting (CSU-ICM) – Targeting Mechanisms of Therapy Resistance PROJECT SUMMARY According to the most recent studies, the average mortality across all cancer types remains at over 30%. To develop transformative solutions to central problems in oncology research, we have established the biennial California State University – Interdisciplinary Cancer Meeting (CSU-ICM). This application is to support the 2020 meeting that will be held on Friday, November 6 at the California State University Northridge, Plaza del Sol Performance Hall. The theme for the 2020 CSU-ICM will be Targeting Mechanisms of Therapy Resistance. Currently, there is a need for cancer research meetings that provide an affordable and focused platform for interdisciplinary exchange between life scientists, non-life scientists and cancer experts. The first CSU-ICM meeting held in 2018 welcomed keynote speaker Dr. Joan Brugge from Harvard Medical School and involved over 150 participants from 10 CSU and 2 UC campuses in California and 1 non-California university. This funding application is based upon preliminary data that we collected from this inaugural event demonstrating diversity of participation at ethnic, discipline, geographic and institute levels. Thus, we postulate that strategic expansion of this meeting will further stimulate novel, collaborative lines of investigation that lead to transformative advances in cancer research and increase diversity in oncology research. The short talk sessions will be chaired by faculty leaders in their respective fields and designed to involve trainees from the undergraduate to postdoctoral levels - increasing the upward mobility of those traditionally underrepresented in cancer research. Involvement of a survivor-advocate will enhance the real need to ensure that even the most basic science research is grounded in clear personal need. The world-renowned keynote speakers ensure the highest quality of scientific exchange. The faculty flash-talk session will highlight ongoing cancer-related work from within the diverse CSU community. Finally, the poster session is designed to foster scientific exchange, networking opportunities and constructive feedback on work-in-progress. In summary, the CSU-ICM is designed to put into action core mission of the California State University system, which includes the advancement of scientific knowledge, learning, and discovery; the promotion of professional development; and the preparation of a diverse scientific workforce while also fulfilling an important need in the broader cancer research community.
R13应用 凯尔伯、塔梅、德·贝拉德、伯穆德斯 标题:加州州立大学-跨学科癌症会议(CSU-ICM)-靶向 治疗抵抗的机制 项目总结 根据最新的研究,所有癌症类型的平均死亡率 保持在30%以上。为肿瘤学的中心问题开发变革性的解决方案 研究,我们成立了两年一度的加州州立大学-跨学科 癌症会议(CSU-ICM)。这项申请是为了支持2020年的会议, 于11月6日星期五在加州州立大学北岭广场举行 演奏厅。2020年CSU-ICM的主题将是 治疗阻力。目前,有必要召开癌症研究会议,提供 一个负担得起的、专注于生命科学家之间跨学科交流的平台, 非生命科学家和癌症专家。欢迎2018年首次CSU-ICM会议 来自哈佛医学院的主讲人Joan Brugge博士,有150多人参加 参与者来自加州的10个CSU校区和2个加州大学校区,以及1个非加州校区 上大学。这份资金申请是基于我们从以下地点收集的初步数据 这一首届活动展示了种族、纪律、 地理和学院两级。因此,我们假设这一战略扩张 会议将进一步刺激新的、合作的调查路线,从而导致 癌症研究的变革性进展和肿瘤学研究的多样性。 简短的讲座将由各自领域的教职员工领导主持 旨在让从本科生到博士后级别的实习生参与-增加 那些传统上在癌症研究中代表性不足的人的向上流动性。 幸存者权益倡导者的参与将增强确保即使是 大多数基础科学研究都是基于明确的个人需求。举世闻名的 主旨演讲者确保最高质量的科学交流。教职员工的闪电谈话 会议将重点介绍CSU内部正在进行的与癌症相关的工作 社区。最后,海报会议旨在促进科学交流, 建立联系的机会和对正在进行的工作的建设性反馈。总而言之, CSU-ICM旨在将加州州立大学的核心使命付诸实践 系统,包括科学知识、学习和发现的进步; 促进专业发展;以及准备多样化的科学 同时还满足了更广泛的癌症研究中的重要需求 社区。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID G BERMUDES其他文献

DAVID G BERMUDES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID G BERMUDES', 18)}}的其他基金

Tumor-targeting Salmonella expressing apoptosis-inducing cytotoxic proteins
表达细胞凋亡诱导细胞毒性蛋白的肿瘤靶向沙门氏菌
  • 批准号:
    8414763
  • 财政年份:
    2013
  • 资助金额:
    $ 0.5万
  • 项目类别:
Tumor-targeting Salmonella expressing apoptosis-inducing cytotoxic proteins
表达细胞凋亡诱导细胞毒性蛋白的肿瘤靶向沙门氏菌
  • 批准号:
    8660303
  • 财政年份:
    2013
  • 资助金额:
    $ 0.5万
  • 项目类别:
Tumor-targeting Salmonella expressing apoptosis-inducing cytotoxic proteins
表达细胞凋亡诱导细胞毒性蛋白的肿瘤靶向沙门氏菌
  • 批准号:
    9026621
  • 财政年份:
    2013
  • 资助金额:
    $ 0.5万
  • 项目类别:
Tumor-targeting Salmonella expressing apoptosis-inducing cytotoxic proteins
表达细胞凋亡诱导细胞毒性蛋白的肿瘤靶向沙门氏菌
  • 批准号:
    8827374
  • 财政年份:
    2013
  • 资助金额:
    $ 0.5万
  • 项目类别:
TUMOR-TARGETING SALMONELLA EXPRESSING TUMOR-SELECTIVE CYTOTOXIC PROTEINS IN COMBINATION WITH PROTEASE INHIBITORS
表达肿瘤选择性细胞毒性蛋白的肿瘤靶向沙门氏菌与蛋白酶抑制剂的组合
  • 批准号:
    10321211
  • 财政年份:
    2013
  • 资助金额:
    $ 0.5万
  • 项目类别:
Genetic Improvements of Tumor-Targeted Salmonella
针对肿瘤的沙门氏菌的遗传改良
  • 批准号:
    6548941
  • 财政年份:
    2002
  • 资助金额:
    $ 0.5万
  • 项目类别:
SALMONELLA WITH INDUCIBLE ANTICANCER GENES
具有诱导抗癌基因的沙门氏菌
  • 批准号:
    6074570
  • 财政年份:
    2000
  • 资助金额:
    $ 0.5万
  • 项目类别:
REDUCED TOXICITY OF TUMOR-TARGETED SALMONELLA
降低针对肿瘤的沙门氏菌的毒性
  • 批准号:
    2728391
  • 财政年份:
    1998
  • 资助金额:
    $ 0.5万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 0.5万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 0.5万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 0.5万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 0.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了